Natixis Charles River Laboratories International, Inc. Transaction History

Natixis

$17.6 Billion
Q3 2024

A detailed history of Natixis transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, Natixis holds 3,473 shares of CRL stock, worth $683,833. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,473

Previous 3,741 7.16%

Holding current value

$683,833

Previous $772,000 11.4%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$187.96 - $245.29 $50,373 - $65,737	-268 Reduced 7.16%	3,473 $684,000
Q2 2024 Aug 13, 2024	SELL	$206.39 - $268.73 $33,847 - $44,071	-164 Reduced 4.2%	3,741 $772,000
Q1 2024 May 13, 2024	BUY	$203.52 - $273.43 $794,745 - $1.07 Million	3,905 New	3,905 $1.06 Million
Q1 2023 May 12, 2023	BUY	$191.89 - $259.92 $906,104 - $1.23 Million	4,722 New	4,722 $952,000
Q4 2022 Feb 13, 2023	SELL	$197.11 - $250.07 $3.67 Million - $4.66 Million	-18,641 Reduced 60.87%	11,984 $2.61 Million
Q3 2022 Nov 14, 2022	BUY	$182.44 - $250.54 $5.07 Million - $6.97 Million	27,800 Added 984.07%	30,625 $6.03 Million
Q2 2022 Aug 12, 2022	SELL	$204.13 - $302.4 $8.73 Million - $12.9 Million	-42,789 Reduced 93.81%	2,825 $605,000
Q1 2022 May 13, 2022	BUY	$255.51 - $362.11 $7.78 Million - $11 Million	30,439 Added 200.59%	45,614 $13 Million
Q4 2021 Feb 14, 2022	BUY	$351.38 - $448.68 $900,235 - $1.15 Million	2,562 Added 20.31%	15,175 $5.72 Million
Q3 2021 Nov 12, 2021	BUY	$372.64 - $458.3 $2.47 Million - $3.04 Million	6,633 Added 110.92%	12,613 $5.21 Million
Q2 2021 Aug 13, 2021	BUY	$294.17 - $371.65 $1.76 Million - $2.22 Million	5,980 New	5,980 $2.21 Million
Q2 2020 Aug 13, 2020	SELL	$118.84 - $189.72 $7.87 Million - $12.6 Million	-66,200 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$98.9 - $178.34 $614,564 - $1.11 Million	-6,214 Reduced 8.58%	66,200 $8.36 Million
Q4 2019 Feb 14, 2020	SELL	$126.05 - $152.76 $4.47 Million - $5.42 Million	-35,450 Reduced 32.87%	72,414 $11 Million
Q3 2019 Nov 13, 2019	BUY	$125.07 - $143.67 $8.66 Million - $9.95 Million	69,281 Added 179.56%	107,864 $14.3 Million
Q2 2019 Aug 13, 2019	SELL	$123.4 - $148.55 $13 Million - $15.6 Million	-105,076 Reduced 73.14%	38,583 $5.48 Million
Q1 2019 May 15, 2019	BUY	$104.82 - $146.73 $9.72 Million - $13.6 Million	92,692 Added 181.87%	143,659 $20.6 Million
Q4 2018 Feb 14, 2019	SELL	$105.09 - $137.23 $3.65 Million - $4.76 Million	-34,721 Reduced 40.52%	50,967 $5.77 Million
Q3 2018 Nov 14, 2018	BUY	$112.11 - $134.54 $4.78 Million - $5.74 Million	42,666 Added 99.17%	85,688 $11.5 Million
Q2 2018 Aug 14, 2018	BUY	$102.37 - $117.25 $4.4 Million - $5.04 Million	43,022 New	43,022 $4.83 Million
Q4 2017 Feb 14, 2018	SELL	$100.43 - $118.09 $314,546 - $369,857	-3,132 Closed	0 $0
Q3 2017 Nov 14, 2017	SELL	$96.72 - $109.26 $4,449 - $5,025	-46 Reduced 1.45%	3,132 $338,000
Q2 2017 Aug 14, 2017	BUY	N/A	3,178	3,178 $321,000

Others Institutions Holding CRL

# of Institutions

691

Shares Held

52.3M

Call Options Held

226K

Put Options Held

410K

View Full List

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Ticker CRL
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 50,863,300
Market Cap $10B
Description
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...

More about CRL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.

Account